{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"Is kratom legal in the United States?","acceptedAnswer":{"@type":"Answer","text":"Kratom is legal at the federal level but banned in seven states: Alabama, Arkansas, Indiana, Louisiana, Vermont, and Wisconsin. Rhode Island reversed its ban effective April 1, 2026. Over a dozen states have passed the Kratom Consumer Protection Act (KCPA) to regulate rather than prohibit kratom."}},{"@type":"Question","name":"Which states have banned kratom?","acceptedAnswer":{"@type":"Answer","text":"As of 2026, kratom is banned in Alabama (2016), Arkansas (2016), Connecticut (2026), Indiana (2014), Louisiana (2025), Vermont (2016), and Wisconsin (2014). Rhode Island's ban was reversed in 2025, with legal sales beginning April 1, 2026."}},{"@type":"Question","name":"What is the Kratom Consumer Protection Act (KCPA)?","acceptedAnswer":{"@type":"Answer","text":"The KCPA is model legislation that regulates kratom products by requiring age verification (21+), product labeling, lab testing, and banning adulterated or synthetic products. It has been enacted in 18+ states including Arizona, Colorado, Georgia, Nevada, Oregon, Utah, and Virginia."}},{"@type":"Question","name":"Did the DEA try to ban kratom?","acceptedAnswer":{"@type":"Answer","text":"Yes. In August 2016, the DEA announced plans to emergency schedule mitragynine and 7-hydroxymitragynine as Schedule I substances. After unprecedented public backlash—including 142,000+ public comments, a petition with 140,000+ signatures, and letters from 51 members of Congress—the DEA withdrew its notice in October 2016."}},{"@type":"Question","name":"What did the WHO say about kratom?","acceptedAnswer":{"@type":"Answer","text":"In October 2021, the WHO Expert Committee on Drug Dependence (ECDD) completed a critical review of kratom and recommended against international scheduling, concluding there was insufficient evidence of harm to warrant placing kratom under international control."}},{"@type":"Question","name":"Can I travel with kratom across state lines?","acceptedAnswer":{"@type":"Answer","text":"You should never transport kratom into states where it is banned, as you could face criminal charges for possession of a controlled substance. Plan travel routes to avoid Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, and Wisconsin. Also check for local bans in cities like San Diego, CA and Sarasota County, FL."}},{"@type":"Question","name":"Is kratom an traditional substance?","acceptedAnswer":{"@type":"Answer","text":"Kratom is not classified as an traditional substance. It is a botanical from the coffee family (Rubiaceae) whose alkaloids interact with alkaloid receptors as partial agonists. Scientists have noted kratom's pharmacology differs significantly from classical traditional substances, with a lower risk profile for respiratory low mood."}},{"@type":"Question","name":"Why did Louisiana ban kratom in 2025?","acceptedAnswer":{"@type":"Answer","text":"Louisiana's SB 154, effective August 1, 2025, reclassified mitragynine and 7-hydroxymitragynine as Schedule I controlled substances. The legislation was driven largely by concerns over adulterated and enhanced kratom products containing unnaturally high concentrations of 7-hydroxymitragynine."}},{"@type":"Question","name":"Has the FDA approved kratom for any wellness use?","acceptedAnswer":{"@type":"Answer","text":"No. The FDA has not approved kratom for any wellness use and has issued multiple public health advisories against its use. However, the agency's 2017 recommendation to the DEA to schedule kratom was challenged by scientists who found significant errors in the FDA's 8-factor analysis."}},{"@type":"Question","name":"What happens if I'm caught with kratom in a banned state?","acceptedAnswer":{"@type":"Answer","text":"Penalties vary by state. In Louisiana, possession carries up to 5 years in prison. Alabama and Arkansas manage kratom as a Schedule I controlled substance with penalties similar to other prohibited drugs. Indiana and Wisconsin classify kratom alkaloids as synthetic substances with corresponding penalties."}}]}
Key Takeaway
As of April 2026, kratom is legal under U.S. federal law but banned in seven states (Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, Wisconsin). Rhode Island reversed its ban effective April 1, 2026. Eighteen-plus states have adopted the Kratom Consumer Protection Act (KCPA), which regulates rather than prohibits kratom by requiring 21+ age verification, lab-tested products, and accurate labeling. Always check local law before traveling with kratom — state-level enforcement varies dramatically.
The kratom legal status in the United States is a patchwork of state laws, federal agency actions, and international reviews that has evolved dramatically over the past decade. As of 2026, kratom remains legal at the federal level but is banned in seven states, regulated under the Kratom Consumer Protection Act in over a dozen others, and exists in a legal gray area in cities and counties that have imposed their own restrictions.
This article provides the definitive guide to the kratom ban landscape, the complete FDA and DEA timeline, the growing KCPA movement, and what the future holds for kratom consumers across the country. Whether you’re checking is kratom legal in your state or trying to understand the federal regulatory history, this is the comprehensive resource you need.
Where is kratom legal in the United States today?
Kratom occupies a unique position in American drug policy. The Drug Enforcement Administration (DEA) has not classified it as a controlled substance at the federal level, meaning it is legal under federal law. However, individual states retain the authority to regulate or ban substances within their borders, and seven states have done so.
The broader trend since 2019 has moved decisively toward regulation over prohibition. More than two dozen states and the District of Columbia now have some form of kratom regulation in place. The Kratom Consumer Protection Act—model legislation developed by the American Kratom Association (AKA)—has been the primary vehicle for this regulatory approach, establishing product safety standards, age restrictions, and labeling requirements rather than outright bans.
Rhode Island made history in 2025 by becoming the first state to reverse a kratom ban, signing the Rhode Island Kratom Act and establishing a regulated market effective April 1, 2026. Meanwhile, Louisiana moved in the opposite direction, enacting one of the most severe bans in the country in August 2025.
Which states have banned kratom?
As of March 2026, seven states maintain complete bans on kratom possession, sale, and distribution.[10] These bans classify kratom’s primary alkaloids—mitragynine and 7-hydroxymitragynine—as controlled substances.
| State | Year Banned | Classification | Key Details |
|---|---|---|---|
| Indiana | 2014 | Synthetic drug | One of the first states to ban; classifies kratom alkaloids as synthetic substances |
| Wisconsin | 2014 | Schedule I | Banned alongside Indiana as an early prohibitor; classifies mitragynine as Schedule I |
| Alabama | 2016 | Schedule I | Targets mitragynine and 7-hydroxymitragynine specifically as controlled substances |
| Arkansas | 2016 | Schedule I | Classified under state controlled substances list; strong opposition from health officials |
| Vermont | 2016 | Regulated drug | Implemented through Board of Health administrative action rather than legislation |
| Louisiana | 2025 | Schedule I | SB 154 effective Aug 1, 2025; places kratom in same category as heroin and LSD; up to 5 years for possession |
| Connecticut | 2026 | Schedule I | HB 6855 signed March 2026; Schedule I classification; announced by Lt. Gov Bysiewicz and AG Tong |
Rhode Island was previously on this list, having banned kratom in 2017. However, the state signed the Rhode Island Kratom Act in July 2025, reversing the ban and establishing a regulated framework effective April 1, 2026. This was the first successful reversal of a state-level kratom ban in U.S. history.
Local and Municipal Bans
Even in states where kratom is legal, certain cities and counties have enacted their own prohibitions. Consumers should verify local laws before purchasing or traveling with kratom products:
- San Diego, Oceanside, and Newport Beach, California — Local bans on kratom sales. Additionally, California CDPH launched a statewide enforcement campaign in March 2026 removing kratom products from retail shelves. See our California kratom guide for full details. Kratom is legal at the state level in California
- Sarasota County, Florida — Local ban despite kratom being legal throughout Florida
- Jerseyville, Illinois — Municipal prohibition
- Denver, Colorado — Banned for human consumption, though legal elsewhere in Colorado
- Union County, Mississippi — Local restriction
Which states have adopted the Kratom Consumer Protection Act?
The Kratom Consumer Protection Act represents the most significant legislative success for kratom advocacy. Developed as model legislation by the American Kratom Association, the KCPA provides a framework that protects consumers while addressing legitimate safety concerns through regulation rather than prohibition.
| State | Year Enacted | Notable Provisions |
|---|---|---|
| Utah | 2019 | First state to pass KCPA; established the model framework |
| Arizona | 2019 | Age restriction 18+; labeling requirements |
| Georgia | 2019 | Age restriction 18+; product registration |
| Nevada | 2019 | Labeling and purity standards |
| Oklahoma | 2020 | Age restriction 18+; bans adulterated products |
| Colorado | 2020 | Statewide regulation; note: Denver maintains local ban for human consumption |
| Oregon | 2021 | Comprehensive labeling and testing requirements |
| Virginia | 2021 | Age restriction; product purity standards |
| Mississippi | 2022 | Statewide framework with age restrictions |
| West Virginia | 2022 | Product safety and labeling standards |
| Missouri | 2022 | Age 21+ purchase restriction |
| Kansas | 2023 | Consumer protection and labeling |
| Tennessee | 2023 | Product quality and age restrictions |
| Kentucky | 2023 | Comprehensive product standards |
| North Dakota | 2023 | Age and labeling requirements |
| South Carolina | 2024 | Product regulation framework |
| Maine | 2024 | Consumer safety standards |
| Rhode Island | 2025 (effective April 2026) | First state to reverse a ban; establishes regulated market with tax framework |
Additional states including Texas, New York, Ohio, and Florida allow kratom sales without KCPA-specific legislation, though some have age restrictions or other regulations in place.
What is the complete FDA and DEA kratom timeline?
Understanding today’s kratom legal status requires understanding the decade-long regulatory battle between federal agencies, scientists, advocates, and Congress. The following timeline documents every major event in the federal kratom regulatory story.
| Date | Event | Significance |
|---|---|---|
| 2012 | FDA issues Import Alert 54-15 | First federal action; authorized detention of kratom shipments at the border without examination |
| 2014 | Indiana and Wisconsin enact bans | First state-level prohibitions; classified kratom alkaloids as synthetic substances |
| Feb 2014 | FDA issues second Import Alert | Expanded border seizure authority for kratom products |
| 2016 | Alabama, Arkansas, and Vermont ban kratom | Three additional states enact prohibitions; Vermont acts through Board of Health |
| Aug 30, 2016 | DEA announces emergency scheduling | Published Federal Register notice (Docket No. DEA-442) to place mitragynine and 7-hydroxymitragynine in Schedule I |
| Sep 26, 2016 | Hogan Lovells files formal objection on behalf of AKA | Legal brief argues DEA’s use of emergency scheduling for a natural botanical is “completely unprecedented” |
| Sep 2016 | 51 members of Congress sign bipartisan letter to DEA | Senators and Representatives urge DEA to withdraw scheduling notice and open public comment period |
| Oct 12, 2016 | DEA withdraws emergency scheduling notice | First time DEA reversed an emergency scheduling action; opened unprecedented public comment period |
| Nov 2016 | Pinney Associates publishes 8-Factor Analysis | Independent scientific review concludes kratom does not meet Schedule I criteria; recommends no scheduling |
| Dec 2016 | DEA receives 142,000+ public comments | Largest public comment response in DEA history; overwhelming opposition to scheduling |
| Nov 2017 | FDA Commissioner Gottlieb issues public health advisory | FDA claims kratom is an traditional substance based on computational modeling; recommends scheduling to DEA |
| Feb 2018 | FDA links kratom to 44 deaths | FDA expands death count; later analysis reveals nearly all cases involved other substances or pre-existing conditions |
| Mar 2018 | AKA publishes rebuttal of FDA death data (Jane Babin, Ph.D., Esq.) | Detailed analysis shows FDA’s death claims fail evidentiary standards; only one case involved kratom alone |
| Jun 2018 | Nine leading scientists write to Congressional leadership | Letter urges Congress to prevent scheduling; warns banning kratom would drive traditional substance users back to dangerous drugs |
| Nov 2018 | FDA’s 8-Factor Analysis leaked via FOIA | HHS had recommended Schedule I; scientists publish detailed critique identifying significant errors |
| 2019 | First KCPA states: Utah, Arizona, Georgia, Nevada | States begin choosing regulation over prohibition; establishes KCPA as viable model |
| Oct 2021 | WHO Expert Committee reviews kratom | ECDD recommends against international scheduling; finds insufficient evidence of public health risk |
| 2022–2024 | KCPA expansion wave | Multiple states enact consumer protection legislation; total reaches 18+ states |
| Jul 2025 | Rhode Island reverses kratom ban | First-ever ban reversal; signs KCPA effective April 1, 2026 |
| Aug 2025 | Louisiana SB 154 takes effect | Classifies kratom as Schedule I; up to 5 years for possession; driven by concerns over enhanced products |
What happened with the 2016 DEA emergency scheduling attempt?
The most pivotal moment in kratom’s regulatory history came on August 30, 2016, when the DEA published a Federal Register notice announcing its intent to temporarily place mitragynine and 7-hydroxymitragynine—kratom’s two primary alkaloids—into Schedule I of the Controlled Substances Act (DEA Docket No. DEA-442). [1]
The notice cited kratom as posing “an imminent hazard to public safety,” invoking emergency scheduling authority under 21 U.S.C. § 811(h). As legal experts at Hogan Lovells noted in their formal objection on behalf of the AKA, this use of emergency scheduling was “completely unprecedented” for a natural botanical product with decades of documented safe use. [2] The emergency scheduling provision was designed for novel synthetic “designer” substances that emerge rapidly on illicit markets—not for a well-known plant in the coffee family (Hogan Lovells, 2016).
The proposed scheduling would have criminalized possession of kratom overnight, affecting an estimated 3–5 million American consumers at the time. The legal consequences would have been identical to possessing heroin or LSD.
How did scientists and Congress push back against DEA scheduling?
The response to the DEA’s scheduling attempt was unlike anything the agency had experienced. Within weeks, a powerful coalition of scientists, lawmakers, consumer advocates, and everyday Americans mobilized in opposition.[11]
Congressional Opposition
In September 2016, a bipartisan group of 51 members of Congress—including both senators and representatives—signed a letter to then-Acting DEA Administrator Chuck Rosenberg urging the agency to withdraw its emergency scheduling notice. [3] The letter called for a public comment period and proper scientific review before any scheduling action, arguing that the DEA had failed to follow standard procedures (U.S. Senate Letter to DEA, 2016).
The Scientific Community Responds
Pinney Associates, an independent scientific consulting firm, published a comprehensive 8-Factor Analysis in November 2016 [4] evaluating kratom under the same criteria the Controlled Substances Act requires for scheduling decisions. Their 127-page analysis concluded that kratom did not meet the criteria for Schedule I placement: its abuse potential was low, its pharmacological profile differed significantly from classical traditional substances, and existing evidence did not support a finding of imminent public safety hazard (Pinney Associates, 2016).
In June 2018, nine of the nation’s leading kratom researchers wrote directly to Congressional leadership [7]—including Majority Leader McConnell, Speaker Ryan, Minority Leader Pelosi, and Minority Leader Schumer. Their letter stated unequivocally: “Based on the substantial science and safety signal data, we conclude that kratom does not meet the statutorily mandated criteria for Schedule I substances.” The scientists warned that banning kratom would have a “foreseeable negative public health consequence” by driving thousands of former traditional substance users back to dangerous drugs (Kratom Scientist Letter to Congressional Leaders, 2018).
Unprecedented Public Response
The DEA’s reversal on October 12, 2016, was itself unprecedented—the first time the agency had ever withdrawn an emergency scheduling notice. The subsequent public comment period generated over 142,000 comments, the largest in DEA history, with the overwhelming majority opposing scheduling.
Challenging the FDA’s Evidence
When the FDA’s Commissioner Scott Gottlieb issued a public health advisory in November 2017 claiming kratom was an “traditional substance” and linking it to 44 deaths, the scientific and advocacy community responded with detailed rebuttals. Dr. Jane Babin’s analysis for the AKA found that the FDA’s death data was fundamentally flawed [5]: “the overwhelming majority of the cited deaths fails to provide a cohesive or reasonable scientific basis to conclude any of the deaths was caused by kratom.” Nearly all cases involved polysubstance use or pre-existing wellness conditions (Babin, 2018).
When the FDA’s own 8-Factor Analysis recommending Schedule I placement was leaked through a FOIA request in November 2018, scientists published a comprehensive critique identifying significant methodological errors, selective data presentation, and conclusions unsupported by the evidence presented [6] (Scientists’ Response to FDA’s 8-Factor Analysis, 2018).
What did the WHO decide about kratom in 2021?
In October 2021, the World Health Organization’s Expert Committee on Drug Dependence (ECDD) completed a critical review of kratom (Mitragyna speciosa) during its 44th meeting. After evaluating the available scientific evidence, the ECDD recommended against placing kratom under international control. [8][9]
The WHO’s pre-review report acknowledged kratom’s pharmacological activity at alkaloid receptors but noted the significant differences between kratom and classical traditional substances, particularly regarding respiratory low mood risk. The committee found insufficient evidence to conclude that kratom posed a significant risk to public health at the international level (WHO ECDD, 2021).
This decision was a landmark moment for kratom advocacy. An unfavorable WHO recommendation could have triggered international scheduling under the Single Convention on Narcotic Drugs, potentially forcing all member nations—including the United States—to ban kratom. The favorable outcome removed that threat and provided a powerful reference point for domestic policy debates.
What is the current federal status of kratom?
As of 2026, kratom’s federal status remains unchanged: it is not a controlled substance under the Controlled Substances Act. The DEA has not moved forward with scheduling since withdrawing its 2016 emergency notice, and the FDA’s 2017 scheduling recommendation to the DEA has not resulted in further action.[12]
The FDA continues to maintain its position that kratom has “no approved wellness uses” and periodically issues consumer advisories. The agency has used its authority to seize kratom products at the border under Import Alert 54-15, and has issued warning letters to companies making unapproved therapeutic claims about kratom products.
However, several developments suggest the federal regulatory posture has softened:
- The WHO’s 2021 decision not to recommend international scheduling removed significant pressure for domestic action
- The growing number of states with KCPA legislation demonstrates a viable regulatory alternative to prohibition
- No new federal scheduling actions have been initiated since 2017
- The National Institute on Drug Abuse (NIDA) has funded research into kratom’s therapeutic potential, particularly for traditional substance use disorder
What does the Kratom Consumer Protection Act actually do?
The Kratom Consumer Protection Act addresses the legitimate concerns that drive kratom ban efforts—product safety, adulteration, and youth access—without criminalizing adult consumers. Core provisions of the KCPA framework include:
- Age restrictions: Prohibits sale to individuals under 18 or 21 (varies by state)
- Product labeling: Requires clear labeling of ingredients, alkaloid content, and manufacturer information
- Adulteration ban: Prohibits the sale of kratom products contaminated with dangerous substances or containing synthetic alkaloids
- 7-OH limits: Some states limit concentrations of 7-hydroxymitragynine to naturally occurring levels, addressing the enhanced product concerns that drove Louisiana’s ban
- Lab testing: Requires third-party testing for contaminants, heavy metals, and alkaloid content
- Penalties for violations: Establishes civil and criminal penalties for selling adulterated or mislabeled products
The KCPA model directly addresses the enhanced product problem. Many recent regulatory concerns stem from products containing unnaturally high concentrations of 7-hydroxymitragynine, which at elevated levels “acts like a powerful traditional substance, which can increase the risk of addiction, overdose, and other serious health effects.” The KCPA framework distinguishes between traditional kratom products with natural alkaloid profiles and potentially dangerous enhanced formulations.
At Amazing Botanicals, all of our lab-tested kratom products meet the highest quality standards. We follow AKA GMP-certified manufacturing processes, and our third-party lab results are available for every batch. We sell only traditional kratom powder and kratom capsules with natural alkaloid profiles—never enhanced or synthetic formulations.
How do I check kratom legality in my state?
Click any state for the full legal guide. Hover for a quick status summary.
Alaska ✅
Arizona ✅
Arkansas ❌
California ⚠️
Colorado ✅
Connecticut ❌
Delaware ✅
Florida ✅
Georgia ✅
Hawaii ✅
Idaho ⚠️
Illinois ⚠️
Indiana ❌
Iowa ✅
Kansas ⚠️
Kentucky ✅
Louisiana ❌
Maine ✅
Maryland ⚠️
Massachusetts ✅
Michigan ⚠️
Minnesota ✅
Mississippi ✅
Missouri ✅
Montana ✅
Nebraska ✅
Nevada ✅
New Hampshire ✅
New Jersey ✅
New Mexico ✅
New York ✅
North Carolina ✅
North Dakota ✅
Ohio ✅
Oklahoma ✅
Oregon ✅
Pennsylvania ✅
Rhode Island ⚠️
South Carolina ✅
South Dakota ✅
Tennessee ⚠️
Texas ✅
Utah ✅
Vermont ❌
Virginia ✅
Washington ✅
Washington D.C. ✅
West Virginia ✅
Wisconsin ❌
Wyoming ✅
🟢 Legal | 🟢 KCPA Regulated | 🟡 Threatened/Complicated | 🔴 Banned — Hover for details, click for full guide
What are the active 2026 threats to kratom legality?
2026 has become one of the most turbulent years for kratom legislation. Several states have active ban bills, and a new federal threat has emerged:
Federal Threat: Senator Ricketts’ Letter to FDA
In March 2026, a group of U.S. Senators led by Senator Pete Ricketts sent a letter to the FDA urging action to schedule kratom federally. This represents the most significant federal-level threat since the 2016 DEA scheduling attempt. The American Kratom Association is mobilizing consumer advocacy at americanadvocacy.org.
States with Active Ban Bills (2026)
| State | Bill | Status | Details |
|---|---|---|---|
| Michigan | HB 5537 | ⚠️ Passed House | Passed House March 18, 2026; now in Senate. Would ban production and sale. |
| Kansas | SB 497 / HB 2365 | ⚠️ Passed Senate 33-5 | Senate voted 33-5 for Schedule I; also snuck into HB 2365 via Conference Committee. |
| Tennessee | HB 1649 | ⚠️ Passed Committee | “Matthew’s Law” — passed Judiciary Committee after emotional family testimony. |
| Illinois | HB 4930 | Introduced | Would ban sales; competing KCPA bills HB 5242 and HB 4737 also introduced. |
| Maryland | HB 1523 / SB 820 | Hearing held | Cross-filed restrictive bills; would take effect July 1, 2026 if passed. |
California CDPH Enforcement Campaign
In March 2026, Governor Newsom announced that the California Department of Public Health (CDPH) achieved a 95% compliance rate for the removal of kratom products from retail businesses. Over 3,308 kratom and 7-OH products were removed from shelves. While not a legislative ban, this represents the most aggressive state enforcement action against kratom retail sales in the country. See our complete California kratom guide.
Defeated Ban Attempts (2026)
- Wyoming — HB 185 (ban) was defeated
- South Dakota — Ban attempt failed
- Arizona — Attempt to classify kratom as a narcotic failed in committee
What is the state-by-state kratom outlook for 2026 and beyond?
The kratom regulatory landscape continues to evolve rapidly. Here’s what to watch in key states:
States Where Bans May Be Reversed
Rhode Island’s successful ban reversal has energized advocacy efforts in other prohibited states. Arkansas and Vermont are the most likely candidates for reconsideration, with active AKA advocacy campaigns underway. Indiana and Wisconsin’s early bans face strong institutional inertia, but Rhode Island’s precedent demonstrates that reversal is possible.
States Considering KCPA Legislation
Several states without existing kratom-specific legislation are considering KCPA bills, including New York, Ohio, and others. As the number of KCPA states grows, pressure increases on remaining states to adopt regulatory frameworks.
Enhanced Product Regulation
Louisiana’s ban was driven primarily by concerns over enhanced kratom products containing concentrated 7-hydroxymitragynine. This issue is likely to drive additional regulation in states that currently have minimal oversight. The KCPA’s provisions addressing adulteration and synthetic alkaloids provide a proven alternative to the blunt instrument of total prohibition.
What practical guidance should kratom consumers follow?
Given the complex and evolving kratom legal status across the country, consumers should take these precautions:
- Verify your local laws: Check both state and local regulations. Visit our kratom legality hub for state-specific information
- Never transport kratom into banned jurisdictions: Possession in a banned state can result in criminal charges regardless of where you purchased the product
- Plan travel routes carefully: Avoid driving through banned states with kratom in your vehicle
- Choose reputable vendors: Purchase from companies that provide third-party lab testing, follow GMP standards, and sell products with natural alkaloid profiles
- Avoid enhanced products: Products with unnaturally high 7-hydroxymitragynine concentrations face increasing regulatory scrutiny and may be driving new ban efforts
- Stay informed: Kratom laws change frequently. Follow the American Kratom Association for legislative updates
Learn more about kratom at our education center, or explore our complete selection of premium kratom products.
Frequently Asked Questions
Is kratom legal in the United States?
Kratom is legal at the federal level but banned in seven states: Alabama, Arkansas, Indiana, Louisiana, Vermont, and Wisconsin. Rhode Island reversed its ban effective April 1, 2026. Over a dozen states regulate kratom through the Kratom Consumer Protection Act. Check our state-by-state guide for the most current information.
Which states have banned kratom?
As of 2026, kratom is banned in Alabama (2016), Arkansas (2016), Connecticut (2026), Indiana (2014), Louisiana (2025), Vermont (2016), and Wisconsin (2014). Rhode Island’s ban was reversed in 2025.
What is the Kratom Consumer Protection Act (KCPA)?
The KCPA is model legislation that regulates kratom by requiring age verification, product labeling, lab testing, and banning adulterated or synthetic products. It has been enacted in 18+ states and represents the primary alternative to prohibition.
Did the DEA try to ban kratom?
Yes. In August 2016, the DEA announced plans to emergency schedule kratom’s alkaloids as Schedule I substances. After unprecedented public opposition—142,000+ comments, 140,000+ petition signatures, and letters from 51 members of Congress—the DEA withdrew its notice in October 2016, the first such reversal in agency history.
What did the WHO say about kratom?
In October 2021, the WHO Expert Committee on Drug Dependence reviewed kratom and recommended against international scheduling, finding insufficient evidence of public health risk to warrant international control.
Can I travel with kratom across state lines?
You should never transport kratom into banned states. Possession in Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, or Wisconsin can result in criminal charges. Also check for local bans in cities like San Diego (CA) and Sarasota County (FL).
Is kratom an traditional substance?
Kratom is not classified as an traditional substance. It is a botanical from the coffee family (Rubiaceae) whose alkaloids interact with alkaloid receptors as partial agonists. Scientists have noted its pharmacology differs significantly from classical traditional substances, with a lower risk profile for respiratory low mood.
Why did Louisiana ban kratom in 2025?
Louisiana’s SB 154 was driven by concerns over adulterated and enhanced kratom products containing unnaturally high concentrations of 7-hydroxymitragynine. The law classifies kratom as Schedule I with penalties up to 5 years for possession.
Has the FDA approved kratom for any wellness use?
No. The FDA has not approved kratom for any wellness use. However, the agency’s 2017 scheduling recommendation was challenged by scientists who identified significant errors in the FDA’s 8-factor analysis, and no scheduling has resulted.
What happens if I’m caught with kratom in a banned state?
Penalties vary. Louisiana carries up to 5 years imprisonment. Alabama and Arkansas manage kratom as a Schedule I substance. Indiana and Wisconsin classify kratom alkaloids as synthetic substances with corresponding criminal penalties.
References
- Drug Enforcement Administration. “Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine Into Schedule I.” Federal Register, Vol. 81, Docket No. DEA-442, August 31, 2016.
- Hogan Lovells US LLP. “Letter to Acting Administrator Chuck Rosenberg Re: Docket No. DEA-442, Emergency Scheduling of Mitragynine and 7-Hydroxymitragynine.” September 26, 2016.
- U.S. Senate. Bipartisan Letter to DEA Regarding Kratom Scheduling. September 2016.
- Pinney Associates. “Assessment of Kratom under the CSA Eight Factors and Scheduling Recommendation.” November 28, 2016.
- Babin, J. “The FDA Kratom Death Data: Exaggerated Claims, Discredited Research, and Distorted Data Fail to Meet the Evidentiary Standard for Placing Kratom as a Schedule I Controlled Substance.” American Kratom Association Policy Report, Vol. 1, March 2018.
- Henningfield, J.E., et al. “Comment on FDA Kratom CSA 8-Factor Analysis.” Letter to HHS, DEA, FDA, and NIDA. November 28, 2018.
- Hemby, S.E., et al. Letter to Congressional Leadership Regarding FDA Scheduling Recommendation for Kratom. June 21, 2018.
- World Health Organization Expert Committee on Drug Dependence (ECDD). “Pre-Review Report: Kratom (Mitragyna speciosa).” 44th ECDD Meeting, October 11–15, 2021.
- World Health Organization. “Summary of Assessments, Findings and Recommendations of the 44th WHO Expert Committee on Drug Dependence.” 2021.
- Legislative Analysis and Public Policy Association. “Regulation of Kratom in America.” 2019.
- Garcia-Romeu, A., et al. “Kratom Policy: The Challenge of Balancing Therapeutic Potential with Public Safety.” Drug and Alcohol Dependence, 2019.
- Pinney Associates. “8-Factor Analysis Update.” 2021.
Shop Lab-Tested Kratom
Browse our full selection of AKA GMP-qualified kratom — powder, capsules, extracts, and more. Free shipping on orders $99+.
Shop All Kratom